Pembrolizumab safe and efficacious in advanced hepatocellular carcinoma Presented ByProf. Shukui Qin, Nanjing University of Chinese Medicine, China TrialPhase 3, KEYNOTE-394 ConferenceASCO GI 2022 21 March, 2022 10:11
HIMALAYA: Durvalumab ± tremelimumab new first-line option for unresectable HCC Presented ByProf. Ghassan Abou-Alfa, Memorial Sloan Kettering Center, NY, USA TrialPhase 3, HIMALAYA ConferenceASCO GI 2022 21 March, 2022 10:05
LAUNCH: TACE plus lenvatinib efficacious in advanced HCC Presented ByProf. Ming Kuang, Sun Yat-sen University, China TrialPhase 3, LAUNCH ConferenceASCO GI 2022 21 March, 2022 10:03
Modest activity of atezolizumab plus bevacizumab in Child-Pugh B HCC Presented ByDr Hyeyeong Kim, Ulsan University Hospital, South Korea TrialPhase 3, IMbrave150 ConferenceASCO GI 2022 21 March, 2022 10:00
Landmark OS for HCC, updated IMbrave150 data Presented ByProf. Richard Finn, UCLA, USA TrialPhase 3, IMbrave150 ConferenceASCO GI 2021 12 March, 2021 11:39
Second-line pembrolizumab after progression on sorafenib benefits OS/PFS in advanced HCC Presented ByProf. Philippe Merle, University Hospital Lyon, France TrialPhase 3, KEYNOTE-240 ConferenceASCO GI 2021 12 March, 2021 11:37
Phase 2 study supports first-line pembrolizumab in advanced HCC Presented ByDr Jean-Luc van Laethem, Hôpital Erasme–Université Libre de Bruxelles, Belgium TrialPhase 2, KEYNOTE-224 ConferenceASCO GI 2021 12 March, 2021 11:35
Yttrium-90 (Y-90) glass microspheres for HCC Presented ByProf. Robert Lewandowski, Northwestern University, Chicago, USA TrialLEGACY ConferenceASCO GI 2021 12 March, 2021 11:33
Sorafenib extends PFS, but not OS, for HCC transcatheter arterial chemoembolisation Presented ByProf. Masatoshi Kudo, Kindai University, Osaka, Japan TrialPhase 2, TACTICS ConferenceASCO GI 2021 12 March, 2021 11:30
In hepatocellular carcinoma, CheckMate 459 misses OS endpoint, but some interesting trends emerge Presented ByDr Thomas Yau, University of Hong Kong, China TrialPhase 3, CheckMate 459 Conference10:28:16pm> hello nurse from conference 26 November, 2019 20:21
